Headspacehealth
-46%
est. 2Y upside i
Rank
#3208
Sector
Digital Health
Est. Liquidity
~3Y
Data Quality
Data: LowThe equity offer has a negative expected upside of -45.75% over 2 years, driven by a stale $3B valuation on $550M ARR (5.45x multiple vs. 2-4x for public peers), high dilution risk, and bearish scenario weighting due to incumbent threats.
Last updated: July 3, 2026
Exit multiple holds at 4.5x on projected $825M revenue (IPO window opens, category leadership solidified), but diluted 20% by a likely capital raise. Net upside ~3.75%.
Exit multiple converges to 3x (in line with public comps) on $825M revenue. After 20% dilution, downside of -37.5%.
Exit multiple compresses to 2x (below comp range) due to incumbent threat and privacy issues. After 20% dilution, downside of -65%.
Preference Stack Risk
moderateFunding Intensity
5830%Total preferred funding $320.9M vs $3B valuation = 10.7% overhang, implying moderate preference risk. All scenarios exceed this threshold, so common equity is not wiped out, but dilution still harms upside.
Dilution Risk
highWith $550M ARR and no profitability data, additional capital likely needed within 24 months, assuming 20% dilution from a down round or flat round.
Secondary Liquidity
noneNo secondary market transactions reported; all equity is illiquid private shares.
Questions to Ask at the Interview
Strategic questions based on Headspacehealth's data — designed to show you've done your homework.
- 1
“How does Headspace plan to differentiate from big tech platforms adding mindfulness features over the next 2 years?”
- 2
“What is the unit economics of the B2B subscription model, and how is churn trending?”
- 3
“What is the expected timeline to liquidity, and is there a secondary market for employee shares?”
Community
Valuation Sentiment
Our model estimates -46% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.